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Analyzing the genes related to
nicotine addiction or schizophrenia
via a pathway and network based
approach
Ying Hu1, Zhonghai Fang1, Yichen Yang1, Dekai Rohlsen-Neal2, Feng Cheng2 & Ju Wang
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The prevalence of tobacco use in people with schizophrenia is much higher than in general population,
which indicates a close relationship between nicotine addiction and schizophrenia. However, the
molecular mechanism underlying the high comorbidity of tobacco smoking and schizophrenia remains
largely unclear. In this study, we conducted a pathway and network analysis on the genes potentially
associated with nicotine addiction or schizophrenia to reveal the functional feature of these genes and
their interactions. Of the 276 genes associated with nicotine addiction and 331 genes associated with
schizophrenia, 52 genes were shared. From these genes, 12 significantly enriched pathways associated
with both diseases were identified. These pathways included those related to synapse function and
signaling transduction, and drug addiction. Further, we constructed a nicotine addiction-specific
and schizophrenia-specific sub-network, identifying 11 novel candidate genes potentially associated
with the two diseases. Finally, we built a schematic molecular network for nicotine addiction and
schizophrenia based on the results of pathway and network analysis, providing a systematic view to
understand the relationship between these two disorders. Our results illustrated that the biological
processes underlying the comorbidity of nicotine addiction and schizophrenia was complex, and was
likely induced by the dysfunction of multiple molecules and pathways.
Schizophrenia is a severe psychiatric disorder with 1% of the life-time prevalence in the general population1,2.
Patients suffering from schizophrenia may show protean manifestations including auditory hallucinations, weird
delusions, significant social withdrawal, difficulty in learning/memory retention, and disorganized speech3.
Currently, there is still no effective treatment for schizophrenia, and those available largely consist in the using
of antipsychotic drugs combined with psychological therapies and other approaches. Thus, developing better
approaches for schizophrenia treatment remains a pressing task for public health1.
Epidemiological studies have shown that individuals with schizophrenia have a higher incidence of substance
use as compared to the general population4–7. Especially, there is a high prevalence of tobacco smoking among
those suffering from the disorder. It has been found that more than 80% of individuals with schizophrenia smoke
and are nicotine dependent, compared to the smoking rate of about 25% in the normal individuals8. Also, patients
suffering from the disorder often smoke high-tar cigarettes and extract more nicotine per cigarette than the common smokers9. Moreover, compared to smokers without mental illness, people with schizophrenia face additional
challenges, making it more difficult for them to quit smoking10,11. Thus, exploring the neurobiological mechanisms that contribute to comorbid nicotine use in schizophrenics is necessary to understand the aetiology and
pathogenesis of schizophrenia, and will be helpful for developing more effective therapeutic strategies to prevent
and treat the two diseases.
From another prospective, the prevalence of smoking among patients with schizophrenia implicates that some
shared neurobiological processes may be responsible for the co-occurrence of the two disorders. One hypothesis
is that the use of tobacco in schizophrenic is mainly driven by self-medication since some psychiatric symptoms of schizophrenia can be relieved by smoking12–14. There are two main arguments for this hypothesis, one is
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that nicotine increases the release of neurotransmitters (e.g., dopamine, glutamate and serotonin) and improves
the performance in memory and attention15,16; the other is that nicotine intake can decrease the side effects of
anti-psychotic drugs17. However, a recent study raised an objection with self-medication hypothesis as the authors
found that cigarette smoking is not associated with cognitive functioning in first-episode psychosis18.
Both genetic and environmental factors play roles in the aetiology and development of schizophrenia and
nicotine addiction. Over the years, many susceptibility genes associated with schizophrenia or nicotine addiction
have been identified1,19–21, some of which are common to both disorders. Nicotine, the main psychoactive ingredient in tobacco and a highly addictive substance, evokes its physiological effects by binding with nicotine acetylcholine receptors (nAChRs) and strengthens reward from brain stimulation. nAChRs also play an essential role in
cognitive processes such as memory and learning22. Actually, several lines of evidence have shown abnormalities
of nAChRs in people with schizophrenia23,24. For example, the levels of several types of nAChRs are decreased
in the brain tissue of postmortem schizophrenia25, which may lead to change in the overall neurotransmitter
release26 and result in some symptoms of schizophrenia24. Accumulating evidences from genetic studies demonstrate an association between schizophrenia and polymorphisms in genes encoding α7 subunit (CHRNA7)27, α4
and β2 subunits (CHRNA4, CHRNB2)28. In addition, COMT gene, a key enzyme in dopamine degradation, may
be involved in nicotine addiction29 or schizophrenia30, or both31. Similarly, polymorphisms in the BDNF, DRD1
and DRD3 genes are associated with nicotine addiction, especially in the schizophrenia populations32. Moreover,
a recent GWAS analysis demonstrates that there is a significant genetic correlation between schizophrenia and
smoking behaviors33.
For complex disorders like schizophrenia or nicotine addiction, multiple genes may be involved in their
aetiology and development. These genes usually function collaboratively to carry out biological functions34.
Consistently, as more and more genes potentially involved in the pathogenesis of schizophrenia and nicotine addiction were identified, multiple-gene-based bioinformatics approaches, such as pathway and network
analysis, have been employed to explore the biological process underlying the schizophrenia35 and nicotine
dependence36. Specifically, pathway-enrichment analysis tools that essentially evolved from methods for gene
expression data analysis can also be used to analyze the genes identified from genetic studies. For example, via
pathway-enrichment analysis, Walsh et al. found neurodevelopment-related pathways, including neuregulin
signaling and glutamate receptor signaling, were overrepresented in genes with structural variants specific to
patients with schizophrenia37. Similar approaches have also been adopted to uncover the pathways associated
with genetic mutations in other disorders, including nicotine addiction and Crohn disease38–40. Under such a
situation, a systematic comparison aiming at revealing the biochemical processes underlying the genes associated
with schizophrenia and nicotine addiction will not only help us to understand the relations of these genes but also
provide further insights into the molecular mechanism related to the high prevalence of tobacco use in people
with schizophrenia.
In this study, we performed a systematic analysis on genes associated with schizophrenia, nicotine addiction,
or both via pathway enrichment analysis and network analysis. By such analyses, we identified the genes, pathways, and protein-protein interaction pairs involved in both disorders. Additionally, the candidate genes associated with both diseases were prioritized based on network and pathway analysis. Finally, a molecular network
related to schizophrenia and nicotine addiction was constructed to provide a systematic view on the mechanism
underlying the high prevalence of smoking in schizophrenia patients at the molecular level.

Results

NA and SCZ candidate gene sets.

All the candidate genes for nicotine addiction and schizophrenia
disease were retrieved from public resources including published papers and database with high confidence as
described in Method section. 52 common genes (Supplemental Tables S1, S2 and S3) were identified from 276
genes in NAgenes and 331 genes in SCZgenes. Among these shared genes, some genes were associated with neurotransmission systems including dopaminergic neurotransmitter system (e.g., DRD1, DRD2, DRD3, DRD4 and
DRD5), serotonergic neurotransmitter system (e.g., HTR2A, HTR6, TPH1, and TH), glutamatergic neurotransmitter system (e.g., GRIK2, GRIN1, GRIN2A, GRIN2B, GNAS, GRM7 and SLC1A2) and nicotinic neurotransmitter system (e.g., CHRNA7, CHRNB2 and CHRM5). Some genes including SLC1A2, SLC6A3, SLC6A4 and
SLC18A2 were participated in cellular transport system. Besides, drug metabolism related genes could be found
in shared genes such as ADH1B, CYP2D6, GSTM1, GSTT1 and MAOA.
In order to uncover a more specific function pattern of candidate genes, we further performed function
enrichment analysis of these genes related to both diseases. According to the enrichment results exported by
DAVID, 160 biological processes (BP) GO terms were significantly enriched in NAgenes and 167 BP GO terms
were enriched in SCZgenes (Supplemental Tables S4 and S5). Among these terms, 113 terms were shared between
two diseases. As expected, the enriched terms for both diseases basically consisted of synaptic transmission,
transmission of nerve impulse, cell-cell signaling, neurological system process, dopamine metabolic process. The
results were consistent with the fact that the nicotine addiction and schizophrenia disease were both complex
neural system diseases, which also implied that the candidate genes collected are relatively reliable for the following bioinformatics analysis.

Pathway enrichment analysis. For NAgenes, 20 significantly enriched pathways were identified (Table 1).
Of these pathways, some were associated with synaptic transmission, including dopaminergic synapse, cholinergic synapse, and glutamatergic synapse. Some pathways were associated with drug addiction, such as cocaine
addiction, amphetamine addiction, nicotine addiction, morphine addiction, and alcoholism. In addition, pathways including neuroactive ligand-receptor interaction, calcium signaling pathway, and cAMP signaling pathway
were also enriched. Two pathways related to metabolism, i.e., tryptophan metabolism and tyrosine metabolism
were also significantly enriched.
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Pathways

P-value

PBH-value

Genes included

Neuroactive ligandreceptor interaction

4.19 × 10−27 4.24 × 10−25

ADRA2A, ADRB2, AGTR1, CHRM1, CHRM2, CHRM5, CHRNA1, CHRNA10,
CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1,
CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNG, CNR1, DRD1, DRD2, DRD3,
DRD4, DRD5, GABBR1, GABBR2, GABRA2, GABRA4, GABRE, GALR1, GRIK1,
GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN3A, GRM7, HRH4, HTR1F, HTR2A,
HTR6, NPY1R, NPY2R, NR3C1, OPRD1, OPRM1, PARD3

Cocaine addiction

2.10 × 10−16 1.06 × 10−14

BDNF, CREB1, CREB5, DDC, DLG4, DRD1, DRD2, GNAS, GRIN1, GRIN2A,
GRIN2B, GRIN3A, MAOA, MAOB, PPP1R1B, SLC18A2, SLC6A3, TH

Dopaminergic synapse

ARRB2, COMT, CREB1, CREB5, DDC, DRD1, DRD2, DRD3, DRD4, DRD5, GNAS,
4.12 × 10−12 1.39 × 10−10 GRIN2A, GRIN2B, ITPR2, KCNJ6, MAOA, MAOB, PPP1R1B, PPP2R2B, SLC18A2,
SLC6A3, TH

cAMP signaling
pathway

ABCC4, ADRB2, BDNF, CAMK4, CHRM1, CHRM2, CREB1, CREB5, DRD1,
2.30 × 10−11 4.64 × 10−10 DRD2, DRD5, GABBR1, GABBR2, GNAS, GRIN1, GRIN2A, GRIN2B, GRIN3A,
HTR1F, HTR6, NPY, NPY1R, PDE4D, PPP1R1B, RAPGEF3, RHOA

Amphetamine addiction 1.97 × 10−11 4.97 × 10−10

CAMK4, CREB1, CREB5, DDC, DRD1, GNAS, GRIN1, GRIN2A, GRIN2B,
GRIN3A, MAOA, MAOB, PPP1R1B, SLC18A2, SLC6A3, TH

Chemical carcinogenesis 5.14 × 10−11 8.65 × 10−10

ADH1B, CHRNA7, CYP1A1, CYP1B1, CYP2A6, CYP2E1, EPHX1, GSTM1,
GSTM3, GSTP1, GSTT1, NAT1, NAT2, PTGS2, SULT1A1, UGT1A7, UGT2B10

Drug metabolism

3.07 × 10−9

4.42 × 10−8

ADH1B, CYP2A6, CYP2B6, CYP2D6, CYP2E1, FMO1, GSTM1, GSTM3, GSTP1,
GSTT1, MAOA, MAOB, UGT1A7, UGT2B10

Nicotine addiction

6.07 × 10−9

7.67 × 10−8

CHRNA4, CHRNA6, CHRNA7, CHRNB2, GABRA2, GABRA4, GABRE, GRIN1,
GRIN2A, GRIN2B, GRIN3A

Metabolism of
xenobiotics by
cytochrome P450

9.81 × 10−9

1.10 × 10−7

ADH1B, CYP1A1, CYP1B1, CYP2A6, CYP2B6, CYP2D6, CYP2E1, EPHX1, GSTM1,
GSTM3, GSTP1, GSTT1, UGT1A7, UGT2B10

Alcoholism

1.76 × 10−8

1.77 × 10−7

BDNF, CAMK4, CREB1, CREB5, DDC, DRD1, DRD2, GNAS, GRIN1, GRIN2A,
GRIN2B, GRIN3A, MAOA, MAOB, NPY, NTRK2, PPP1R1B, SHC3, SLC18A2,
SLC6A3, TH

Cholinergic synapse

4.92 × 10−8

4.52 × 10−7

CAMK4, CHAT, CHRM1, CHRM2, CHRM5, CHRNA3, CHRNA4, CHRNA6,
CHRNA7, CHRNB2, CHRNB4, CREB1, CREB5, ITPR2, KCNJ6, KCNQ3

Serotonergic synapse

5.60 × 10−8

4.72 × 10−7

CYP2D6, DDC, GNAS, HTR1F, HTR2A, HTR6, ITPR2, KCNJ6, MAOA, MAOB,
PTGS2, RAPGEF3, SLC18A2, SLC6A4, TPH1, TPH2

Morphine addiction

1.04 × 10−6

8.05 × 10−6

ARRB1, ARRB2, DRD1, GABBR1, GABBR2, GABRA2, GABRA4, GABRE, GNAS,
KCNJ6, OPRM1, PDE1C, PDE4D

Calcium signaling
pathway

1.81 × 10−6

1.30 × 10−5

ADRB2, AGTR1, CAMK4, CHRM1, CHRM2, CHRM5, CHRNA7, DRD1, DRD5,
GNAS, GRIN1, GRIN2A, HTR2A, HTR6, ITPR2, NOS2, NOS3, PDE1C

Tryptophan metabolism

1.04 × 10−5

7.03 × 10−5

ALDH2, CYP1A1, CYP1B1, DDC, MAOA, MAOB, TPH1, TPH2

Glutamatergic synapse

1.34 × 10

8.47 × 10

DLG4, GNAS, GRIK1, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN3A, GRM7,
HOMER1, HOMER2, ITPR2, SLC1A2

Tyrosine metabolism

3.80 × 10−5

2.13 × 10−4

ADH1B, COMT, DBH, DDC, MAOA, MAOB, TH

Estrogen signaling
pathway

8.00 × 10−5

4.25 × 10−4

CREB1, CREB5, ESR1, GABBR1, GABBR2, GNAS, ITPR2, KCNJ6, NOS3, OPRM1,
SHC3

Rap1 signaling pathway

6.87 × 10−4

3.31 × 10−3

CNR1, DRD2, FGF12, FGF14, GNAS, GRIN1, GRIN2A, GRIN2B, ITGB3, MAGI1,
PARD3, RAPGEF3, RHOA, SIPA1L2, TEK

Steroid hormone
biosynthesis

9.95 × 10−4

4.37 × 10−3

COMT, CYP17A1, CYP1A1, CYP1B1, CYP2E1, UGT1A7, UGT2B10

−5

−5

Table 1. Pathways Enriched in Genes Associated with Nicotine Addiction.
For SCZgenes, 23 significantly enriched pathways were identified (Table 2). Similar to NAgenes, most of
these pathways were closely related to neuronal functions. Pathways of dopaminergic synapse, glutamatergic
synapse and serotonergic synapse were identified, which were in agreement with the dopamine hypothesis41, glutamate hypothesis42, and serotonergic hypothesis43 of schizophrenia. In addition, signaling transduction-related
pathways, such as calcium signaling pathway, GABAergic synapse and gap junction, long-term depression,
cAMP-mediated signaling, T cell receptor signaling pathway, circadian entrainment, and MAPK signaling pathway were also identified. Furthermore, 5 pathways including cocaine addiction, alcoholism, amphetamine addiction, nicotine addiction, and morphine addiction were enriched in SCZgenes, implying that the pathways related
to drug addiction may play important roles in the origin and development of schizophrenia.
Comparing the pathways associated with the two diseases, there were 8 pathways specific to nicotine addiction, 11 pathways specific to schizophrenia, and 12 shared pathways. These shared pathways include pathways
related to synapse function and signaling transduction (i.e., neuroactive ligand-receptor interaction, dopaminergic synapse, calcium signaling pathway, cAMP signaling pathway, glutamatergic synapse and serotonergic synapse) and pathways related to drug addiction (i.e., nicotine addiction, cocaine addiction, morphine addiction,
amphetamine addiction, and alcoholism). This implies that the drug addiction-associated pathways may play
an essential role in both nicotine addiction and schizophrenia. Some pathways were only significantly enriched
in genes associated with one of the two diseases, but they also included genes involved in the other disorder.
For example, retrograde endocannabinoid signaling, a pathway mainly consisting of neuromodulatory endocannabinoids and their receptors, and playing important role in mediating global modulation of synaptic strength,
localized short-term associative plasticity and cerebellar long term depression, was identified as enriched pathway
for schizophrenia. A close inspection showed that for 20 genes included in this pathway, 12 genes were related
Scientific REPOrTS | (2018) 8:2894 | DOI:10.1038/s41598-018-21297-x
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to schizophrenia, while 6 genes were related to nicotine addiction, and the other 2 genes were associated with
both diseases. Another example is the estrogen signaling, a pathway mainly consisting of hormone estrogen and
its receptors. Besides its function in the reproductive system, this pathway is also involved in multiple biological processes in the peripheral and central nervous systems and plays important roles in cognition, depression,
homeostasis, pain processing, and other associated neuronal functions. The estrogen signaling is significantly
enriched in genes related to nicotine addiction, but for 15 genes included in this pathway, 9 were specific to nicotine addiction and 4 to schizophrenia, as well as 2 common genes for both diseases.

Predicting new candidate genes related to schizophrenia and nicotine addiction.

New genes
potentially related to nicotine addiction and schizophrenia could be predicted by analyzing the susceptibility
genes associated with the two diseases via the human PPI network. NAgenes were mapped to the PPI network and
a NA-specific sub-network with 4,161 nodes was retrieved. The sub-network consists of 247 seed nodes (genes
mapped to PPI network) and 3,914 direct neighbor nodes (genes in PPI that were directly connected to one or
more seed nodes), and 8,524 interactions. Similarly, the SCZ-specific sub-network consisted of 4,724 nodes (306
seed nodes and 4,418 direct neighbor nodes) and 9,474 interactions. There were 1,388 shared nodes and 1,766
shared interactions between these two sub-networks. Among the shared nodes, 91 genes were from NAgenes, 102
genes were from SCZgenes, and 51 genes were common genes for both diseases. There were 1,145 first neighbor
nodes in the shared nodes, from which we identified the new potential risk factors via the ‘guilt-by-association’
principle44. That is, a node tends to participate in the same or similar cellular functions if the majority of its neighbors in the interactome network associated with specific cellular functions (e.g., a certain disease or phenotype).
In our case, 11 genes directly interacted with 5 or more of the 51 common genes were considered as new risk
genes associated with the two diseases, including proto-oncogene tyrosine-protein kinase Fyn (FYN), protein
kinase C alpha (PRKCA), ELAV-like protein 1 (ELAVL1), casein kinase II subunit alpha (CSNK2A1), calmodulin
1 (CALM1), von Hippel–Lindau tumor suppressor (VHL), small ubiquitin-related modifier 1 (SUMO1), growth
factor receptor-bound protein 2 (GRB2), catenin beta-1 (CTNNB1), calcium/calmodulin-dependent protein
kinase type II alpha chain (CAMK2A) and amyloid precursor protein (APP). The network constructed by 11 new
candidate genes and their interacted candidate genes was shown in Fig. 1.

Discussion

For complex diseases, the phenotype or disease status is rarely a straight-forward dysfunction in a specific gene
or pathway, but rather is an interplay between multiple genes that collectively induces the dysfunctional effects
on multiple biological pathways and causes the clinic outcome eventually45,46. Both nicotine addiction and schizophrenia are complex diseases with numerous genes involved in their aetiology and development; meanwhile,
the high prevalence of cigarette smoking in schizophrenia patients implicates a close connection between the two
disorders. The common susceptibility genes related with two diseases may contribute to the association between
the diseases46. Therefore, an analysis on the genes related to nicotine addiction and schizophrenia can help to
uncover their relationship at the molecular level.
Pathway enrichment analysis revealed that several signaling pathways related to neuronal function were
highly enriched in genes related to nicotine addiction or schizophrenia. 12 significantly enriched pathways shared
by both diseases can be divided into two groups: the neurodevelopment-related pathways (including neuroactive
ligand-receptor interaction, dopaminergic synapse, cAMP signaling pathway, calcium signaling pathway, glutamatergic synapse, serotonergic synapse and rap1 signaling pathway) and the drug addiction-related pathways
(including cocaine addiction, nicotine addiction, morphine addiction, amphetamine addiction and alcoholism).
For the neurodevelopment-related pathways, pathways like neuroactive ligand-receptor interaction, cAMP signaling pathway and calcium signaling pathway have been implicated in diseases including nicotine addiction
and schizophrenia. Three pathways associated to non-cholinergic synapse were included and these results were
consistent with prior knowledge about the mechanism of brain diseases47. In detail, stimulating the nicotine acetylcholine receptors (nAChRs) induces changes in intracellular Ca2+ concentration, which further regulates the
release of neurotransmitters such as dopamine, glutamate, and serotonin. These neurotransmitters are essential
in the pathogenic development and treatment of both nicotine addiction48 and schizophrenia49. For example,
dopamine, the most important component in the brain reward system, plays a key role in reinforcing effects of
nicotine50. Meanwhile, even though some symptoms of schizophrenia attribute to a disturbed and hyperactive
dopaminergic signal transduction according to the dopamine hypothesis of schizophrenia41, smoking stimulates
the dopaminergic activity in the brain by increasing the concentration of dopamine and in turn may contribute to antidepressant effects of nicotine molecules in schizophrenia patients. Accordingly, one interpretation
about the high nicotine addiction and schizophrenia comorbidity suggests that smoking represents an attempt to
self-medicate in schizophrenic patients, aiming to reducing extrapyramidal symptoms associated with antipsychotic treatment, and alleviating cognitive deficits associated with schizophrenia51. In addition to dopamine, the
glutamate and serotonin also play a role in ‘the self-medication’ of schizophrenia patients who smoke52. Coupled
with the development of atypical anti-psychotic medications, they have the ability modulate the dopamine neurotransmission release53,54 and reinforce the effect of nicotine. Except the three basal pathways and the three
pathways related to non-cholinergic synapse, rap1 signaling pathway was significantly enriched in both nicotine
addiction and schizophrenia. This pathway was found to be involved in synaptic plasticity, exciting, learning and
memory with inhabiting L-type calcium channel-dependent neurotransmitters release55,56.
We identified five significantly enriched pathways-related to drug addiction, including cocaine addiction,
nicotine addiction, morphine addiction, amphetamine addiction, and alcoholism, were involved in both diseases,
which may imply that the drug addiction related pathways play important roles in the development of schizophrenia. On one hand, our result may provide some clues on the high co-occurrence of substance addiction and
schizophrenia reported by previous studies57–59 from a perspective of pathway dysfunction. On the other hand,
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Pathways

P-value

Neuroactive ligandreceptor interaction

3.29 × 10

Dopaminergic synapse

AKT1, ATF6B, CLOCK, COMT, DRD1, DRD2, DRD3, DRD4, DRD5, GNAL,
1.01 × 10−15 4.73 × 10−14 GNAO1, GNAS, GNB3, GRIA1, GRIA3, GRIA4, GRIN2A, GRIN2B, GSK3B, MAOA,
PPP1R1B, PPP2R2B, PPP3CC, SLC18A1, SLC18A2, SLC6A3, TH

Cocaine addiction

3.06 × 10−14 9.59 × 10−13

−20

PBH-value

Genes included

3.09 × 10

ADRA1A, CCKAR, CHRM5, CHRNA7, CHRNB2, CNR1, DRD1, DRD2, DRD3,
DRD4, DRD5, GABBR1, GABRA1, GABRA6, GABRB2, GABRG2, GABRP, GRIA1,
GRIA3, GRIA4, GRID1, GRIK2, GRIK3, GRIK4, GRIN1, GRIN2A, GRIN2B,
GRIN2D, GRM3, GRM4, GRM5, GRM7, GRM8, HRH1, HRH2, HTR1A, HTR2A,
HTR2C, HTR4, HTR5A, HTR6, HTR7, MCHR1, TAAR6

−18

ATF6B, BDNF, DRD1, DRD2, GNAS, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRM3,
MAOA, PDYN, PPP1R1B, SLC18A1, SLC18A2, SLC6A3, TH

ATF6B, DRD1, GNAS, GRIA1, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B,
Amphetamine addiction 5.97 × 10−14 1.40 × 10−12 GRIN2D, MAOA, PDYN, PPP1R1B, PPP3CC, SLC18A1, SLC18A2, SLC6A3,
STX1A, TH
Glutamatergic synapse

GNAO1, GNAS, GNB3, GRIA1, GRIA3, GRIA4, GRIK2, GRIK3, GRIK4, GRIN1,
3.52 × 10−13 6.61 × 10−12 GRIN2A, GRIN2B, GRIN2D, GRM3, GRM4, GRM5, GRM7, GRM8, PLA2G4A,
PLA2G4C, PPP3CC, SLC1A2, SLC1A6

Serotonergic synapse

CACNA1F, CYP2D6, GABRB2, GNAO1, GNAS, GNB3, HTR1A, HTR2A, HTR2C,
2.09 × 10−12 3.28 × 10−11 HTR3A, HTR4, HTR5A, HTR6, HTR7, MAOA, PLA2G4A, PLA2G4C, PTGS2,
SLC18A1, SLC18A2, SLC6A4, TPH1

Calcium signaling
pathway

ADRA1A, CACNA1F, CCKAR, CD38, CHRM5, CHRNA7, DRD1, DRD5, EGFR,
4.33 × 10−12 5.81 × 10−11 ERBB3, ERBB4, GNAL, GNAS, GRIN1, GRIN2A, GRIN2D, GRM5, HRH1, HRH2,
HTR2A, HTR2C, HTR4, HTR5A, HTR6, HTR7, NOS1, PPP3CC

Nicotine addiction

5.38 × 10−12 6.33 × 10−11

CHRNA7, CHRNB2, GABRA1, GABRA6, GABRB2, GABRG2, GABRP, GRIA1,
GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2D

cAMP signaling
pathway

1.66 × 10−7

1.73 × 10−6

AKT1, BDNF, CACNA1F, DRD1, DRD2, DRD5, FXYD2, GABBR1, GNAS, GRIA1,
GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2D, HTR1A, HTR4, HTR6, NPY,
PDE4B, PPP1R1B

Alcoholism

2.45 × 10−6

2.09 × 10−5

ATF6B, BDNF, DRD1, DRD2, GNAO1, GNAS, GNB3, GRIN1, GRIN2A, GRIN2B,
GRIN2D, MAOA, NPY, PDYN, PPP1R1B, SLC18A1, SLC18A2, SLC6A3, TH

Retrograde
endocannabinoid
signaling

2.24 × 10−6

2.11 × 10−5

CACNA1F, CNR1, GABRA1, GABRA6, GABRB2, GABRG2, GABRP, GNAO1,
GNB3, GRIA1, GRIA3, GRIA4, GRM5, PTGS2

Circadian entrainment

6.03 × 10−6

4.36 × 10−5

GNAO1, GNAS, GNB3, GRIA1, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B,
GRIN2D, NOS1, NOS1AP, PER3

Rap1 signaling pathway

8.33 × 10−5

4.61 × 10−4

AKT1, CNR1, DRD2, EGF, EGFR, FGF1, FGF14, FGF18, FGFR1, GNAO1, GNAS,
GRIN1, GRIN2A, GRIN2B, MAGI1, MAGI2, MAGI3, RAPGEF6

Morphine addiction

1.02 × 10−4

5.33 × 10−4

DRD1, GABBR1, GABRA1, GABRA6, GABRB2, GABRG2, GABRP, GNAO1, GNAS,
GNB3, PDE4B

MAPK signaling
pathway

1.09 × 10−4

5.38 × 10−4

AKT1, BDNF, CACNA1F, EGF, EGFR, FAS, FGF1, FGF14, FGF18, FGFR1, FLNB,
IL1A, IL1B, MAPK8IP2, NTF3, PLA2G4A, PLA2G4C, PPP3CC, TNF, TP53

Cytokine-cytokine
receptor interaction

1.84 × 10−4

8.64 × 10−4

CSF2RA, CSF2RB, CXCR1, EGF, EGFR, FAS, IL10, IL10RA, IL12B, IL18, IL18R1,
IL18RAP, IL1A, IL1B, IL2, IL3, IL3RA, IL4, LTA, TNF

GABAergic synapse

3.52 × 10−4

1.50 × 10−3

CACNA1F, GABBR1, GABRA1, GABRA6, GABRB2, GABRG2, GABRP, GAD1,
GNAO1, GNB3

PI3K-Akt signaling
pathway

1.13 × 10−3

4.19 × 10−3

AKT1, ATF6B, EGF, EGFR, FGF1, FGF14, FGF18, FGFR1, FN1, GNB3, GSK3B, IL2,
IL3, IL3RA, IL4, PPP2R2B, RELN, TNXB, TP53, YWHAE, YWHAH, YWHAZ

Phospholipase D
signaling pathway

1.5 × 10−3

4.53 × 10−3

AKT1, CXCR1, EGF, EGFR, GNAS, GRM3, GRM4, GRM5, GRM7, GRM8,
PLA2G4A, PLA2G4C

ErbB signaling pathway

1.37 × 10−3

4.61 × 10−3

AKT1, EGF, EGFR, ERBB3, ERBB4, GSK3B, NRG1, NRG2, NRG3

T cell receptor signaling
pathway

1.33 × 10

4.61 × 10

AKT1, CD4, CTLA4, GSK3B, IL10, IL2, IL4, ITK, PPP3CC, TNF

Gap junction

1.49 × 10−3

4.66 × 10−3

DRD1, DRD2, EGF, EGFR, GNAS, GRM5, HTR2A, HTR2C, TUBA8

Long-term depression

2.34 × 10−3

6.46 × 10−3

GNAO1, GNAS, GRIA1, GRIA3, NOS1, PLA2G4A, PLA2G4C

−3

−3

Table 2. Pathways Enriched by Genes Associated with Schizophrenia.
our results show that the membrane receptor proteins participating in drug addiction pathways, such as nAChRs
and μ opioid receptor (MOR), may be the potential target for therapeutic treatment for schizophrenia. In fact, the
participation of several subtypes of neuronal nAChRs has been explored as therapeutic targets for treatment of
various diseases such as pain, schizophrenia and Alzheimer’s disease60. Earlier study has found that the expression
level of MOR mRNA is higher in schizophrenia, which may contribute to suppressed GABA neuron activity in
prefrontal cortical which result in cognitive impairments in schizophrenia61. Besides, a recent study demonstrated
that genetic variation of MOR in schizophrenics was closely related to their smoking differences62. However,
the utilization of MOR in the therapeutic treatment for both nicotine addiction and schizophrenia still requires
further investigation.
Through network analysis, we found that a large number of dysfunctional PPI pairs involved in nicotine
addiction or schizophrenia, and several common PPI pairs co-occurrence in both diseases were employed to
construct a common sub-network for both diseases. By calculating the degree parameter of each node in this
common sub-network, we identified 11 susceptible genes potentially involved in both diseases. Most of these
genes have been reported to be associated with nicotine addiction, schizophrenia or both diseases through
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Figure 1. The predicted candidate genes and genes interacted with them in human PPI. Nodes shown in white,
grey, and black represent genes associated with schizophrenia, nicotine addiction, or both diseases, respectively.
The round rectangle nodes represent genes predicted to be associated with schizophrenia and nicotine addiction
based on their network feature.
various experimental approaches (Supplemental Table S6). Taking FYN for example, as a member from the tyrosine kinase in Src family, this gene is an important component for various cellular processes including synaptic
plasticity63. It is abundantly expressed in the hippocampus, cerebral cortex, and thalamus and has a key role in
long-term potentiation (LTP) and in the relation of LTP to spatial learning and memory64. This gene has been
proved to be associated with both nicotine addiction and schizophrenia65–67; e.g., it can increase the activity of
NMDA receptor by regulating the glutamatergic signaling and further influences the performance in schizophrenics, and is implicated in the development of nicotine addiction via interaction with α7 nAChR. In addition,
for some of these novel genes (e.g., CALM1 and ELAVL1), although no available study has demonstrated their
connection with schizophrenia or nicotine addiction directly, they have been identified as risk factors for other
mental disorders including autism and drug addictions. Besides, these genes were included in multiple pathways
enriched in the genes associated with one or both diseases. For example,CALM1 is a common component for
6 enriched pathways such as alcoholism, amphetamine addiction, calcium signaling pathway, cAMP signaling
pathway, dopaminergic synapse and Rap1 signaling pathway. The involvement of these new susceptible genes
pathways associated with both nicotine addiction and schizophrenia provides further evidence for their connection with the two diseases. Thus, these genes may be new candidates for further exploration.
Based on the results from pathway analysis and network analysis, the relationship of nicotine addiction and
schizophrenia could be summarized into a schematic network (Fig. 2). This network consists of a number of key
genes, transmembrane receptors and neurotransmitters associated with the two diseases. In addition, the common pathways enriched for two diseases including neurotransmitters receptor signaling transduction pathways
and intracellular signaling transduction cascades were also included, i.e. dopamine synapse, glutamateric synapse, nicotine addiction and cAMP signaling pathways, etc. Such a network was a combination of drug addiction
and schizophrenia-related networks and illustrated that the overlapped part of two molecular networks were
essential in understanding the high nicotine addiction and schizophrenia comorbidity. Of note, the new candidate genes predicted by network analysis can be found in the network which illustrated these new risk factors with
high confidence. Moreover, via CaM and PKC many loops were interlinked, further indicating that their important roles in nicotine addiction and schizophrenia. As protein kinases, PKC participates in a wide variety of cellular processes including neurodevelopment. CaM is a multifunctional intermediate calcium-binding messenger
protein and acting as part of a calcium signal transduction pathway, CaM also regulates several cellular processes
Scientific REPOrTS | (2018) 8:2894 | DOI:10.1038/s41598-018-21297-x
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Figure 2. A systematic network of the molecular mechanism underlying schizophrenia and nicotine addiction.
This network was built based on the results of pathway analysis and network analysis. Nodes shown in white,
grey, and black rectangles represent genes related to schizophrenia, nicotine addiction, or both diseases,
respectively. The predicted candidate genes are shown by larger rectangles with bold border. Ellipses represent
neurotransmitters like GABA, serotonin, dopamine and glutamate. Dashed and solid lines represent indirect
and direct regulations; lines with arrow and spot represent activation and inhibition, respectively.
by modifying its interactions with various target proteins such as kinases or phosphatases. Both CaM and PKC
are key components for pathways associated to synaptic plasticity and remodeling. Additionally, according to a
previous study68, the synaptic can rapidly remodel by PKC through reciprocal translocation of NMDA receptors
and CaMKII (which is a protein kinase regulated by the Ca2+/CaM complex), suggesting that a direct/indirect
link between PKC and CaMKII is existent, which may enhance the crosstalk of the pathways in our molecular
network.
Nevertheless, there are some limitations in this study. For instance, the pathway-related gene annotation system in KEGG database and PPI network constructed by integrating the published articles may be incomplete due
to the limitation of current technology. However, some meaningful and novel interpretation can be found for the
association between nicotine addiction and schizophrenia. Moreover, the schizophrenia and nicotine dependence
molecular network based on the results of pathway enrichment analysis and network analysis provides a systematic view for understanding the high prevalence tobacco use in schizophrenia.
In summary, we performed a systematic analysis on the susceptive genes related to nicotine addiction and
schizophrenia and built the pathogenetic association between two diseases based on pathways enrichment analysis and network analysis. We identified the pathways that may be responsible for the high nicotine addiction and
schizophrenia comorbidity. In addition, through network analysis we identified the PPI pairs shared by nicotine
addiction and schizophrenia, as well as novel genes potentially linked to the etiology and development of the
diseases. Our results may provide an alternative view on exploring the linkage between nicotine addiction and
schizophrenia, and suggest that a system level approach used in this work can be promising for understanding the
pathogenetic association between diseases.

Methods

Data collection. In this study, the susceptibility genes related to nicotine addiction or schizophrenia were
collected from three sources including core genes correlated with two diseases, prioritized genes based on mathematic methods, and genes extracted from association study. For nicotine addiction related genes, based on human
genetics studies, Li and Burmeister21 compiled a list of 49 genes related to nicotine addiction, which were selected
as core genes for nicotine dependence. Liu et al. obtained 220 genes potentially related to nicotine dependence
via a multi-source gene prioritization approach69. In addition, 267 genes reported to be positively associated with
nicotine addiction in the association studies were also provided by Liu et al.69. A combination of these three lists
resulted in a set of 276 unique genes (denoted as NAgenes, hereafter).
Schizophrenia-related genes were extracted from the following databases: SchiZophrenia Gene Resource70
(SZGR: https://bioinfo.uth.edu/SZGR/). This database provides a comprehensive online resource for schizophrenia genetic studies, from which 38 core genes were collected by manual, 218 genes prioritized from
multi-dimensional evidences and 278 genes identified from schizophrenia-related association studies were
retrieved71. A combination of the three lists resulted in a set of 331 unique genes (denoted as SCZgenes, hereafter).
To construct the human protein-protein interaction (PPI) network, we obtained the Protein Interaction
Network Analysis (PINA) database72 by pooling and curating the unique physical interaction information from
six main public protein interaction databases, i.e., BioGRID, IntAct, DIP, MINT, MIPS/MPact, and HPRD. After
excluding the redundant and self-interacting pairs, a human PPI network containing 15,093 nodes and 161,419
edges was constructed.
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Gene ontology annotation of gene data. The functional features of NAgenes and SCZgenes were examined to evaluate the relevance of the gene sets to the nicotine addiction or schizophrenia. By means of Gene
Ontology (GO) enrichment analysis, the major biological processes that the gene sets involved could be recognized. Here, the online analysis tool DAVID73 was used to perform the GO biological processes enrichment
analysis and the exported GO terms whose FDR value were less than 0.05 was selected.

Pathway enrichment analysis. The biochemical pathways enriched in NAgenes and SCZgenes were iden-

tified by functional module ClueGO74 in Cytoscape75. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database76 was used for pathway enrichment analysis. In ClueGO, the candidate genes were mapped to each
of the pathways. Then, a significant value (p value) was assigned to measure the significance that the genes of
interest participate in a certain pathway based on hypergeometric test. Finally, the corresponding multiple testing
correction p-value was calculated with the Benjamini-Hockberg method77. Here, the enriched pathways were
identified according to the following threshold: PBH < 0.01.

New candidate genes related to both diseases prediction based on network analysis. We
mapped the NAgenes and SCZgenes to human PPI network separately and obtained the NA-specific sub-network
and SCZ-specific sub-network which containing relevant seed nodes and the first neighbor nodes (direct interacting nodes with seed nodes). Then we extracted the common PPI pairs in the both sub-network and constructed
a new common sub-network for both diseases. Using the “Network Analyzer”78 plug-in in Cytoscape, we calculated the degree of the each node in the sub-network. After removing the NAgenes and SCZgenes, the remaining
genes could be regarded as new candidate genes for both diseases. We selected the new candidate genes with
degrees ≥ 5, i.e., genes directly connected with 5 or more of the shared genes in both nicotine addiction and schizophrenia. The selected genes were regarded as risk factors that may contribute to the pathogenetic association
between nicotine addiction and schizophrenia.
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